 Home > Active Ingredient News > Antitumor Therapy > Long-term follow-up of boron neutron capture therapy for recurrent malignant meningioma

Long-term follow-up of boron neutron capture therapy for recurrent malignant meningioma

 Last Update: 2023-02-03
 Source: Internet
 Author: User

Tags

3 4 inches

coolant type 2

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Satoshi Takai et al.
of the Department of Neurosurgery, Osaka Medical University, Japan, retrospectively analyzed 44 patients
with relapsed and refractory meningiomas treated with BNCT and long-term follow-up from 2005 to 2019.

The results were published in the January 2022 issue of the journal
Neuro-Oncology.

- Excerpted from the article chapter

【Ref: Takai S, et al.
Neuro Oncol.
2022 Jan 5; 24(1):90-98.
doi: 10.
1093/neuonc/noab108.
】

Research background

High-grade meningioma (HGM), especially relapsed and refractory meningioma, is poorly treated, and there is currently no standard treatment regimen
.

Boron Neutron Therapy (BNCT) is a new type of particle radiotherapy that can theoretically selectively kill tumor cells and is a biological cell-targeted radiotherapy
.

Satoshi Takai et al.
of the Department of Neurosurgery, Osaka Medical University, Japan, retrospectively analyzed 44 patients
with relapsed and refractory meningiomas treated with BNCT and long-term follow-up from 2005 to 2019.

The results were published in the January 2022 issue of the journal
Neuro-Oncology.

Study results

The researchers evaluated
tumor size, overall survival (OS) and progression-free survival (PFS) after BNCT, and the reasons for treatment failure in 44 patients.

The results showed that the median OS after BNCT was 29.
6 months (95% CI: 16.
1-40.
4)
in all patients.

The median follow-up after BNCT was 26 months (6.
4-103).

Among them, the median OS after BNCT for WHO grade 2 (20 cases) and WHO grade 3 (24 cases) meningioma was 44.
4 months and 21.
55 months, respectively (P=0.
0009).

After 36 high-grade meningiomas BNCT treatment, 35 cases showed tumor shrinkage on imaging after 3 months; PFS after BNCT was 13.
7 months (95% CI: 8.
3 to 28.
6).

The median PFS after BNCT was 24.
3 months and 9.
4 months (6.
3-14.
4) (P=0.
0024) in WHO grade 2 and WHO grade 3 meningiomas, respectively, and local recurrence
was observed in only 22.
2% of patients.

Conclusion of the study

In summary, most patients with relapsed and refractory meningiomas have relatively large tumors and a high proportion of WHO grade 3, which seems to have a poor
prognosis.

However, treatment with reactor BNCT yields good survival rates
.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.